Accelerate Diagnostics, Inc. Names Frank J. M. ten Brink to Board of Directors

Mar 06, 2013, 06:00 ET from Accelerate Diagnostics, Inc.

TUCSON, Ariz., March 6, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), a developer of automated diagnostic systems for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens, announced today that Frank J.M. ten Brink has been appointed to its board of directors.

Mr. ten Brink has more than 16 years of finance, accounting and merger & acquisition experience in high-growth environments. He is currently serving as executive vice president, chief financial officer and chief administrative officer of Stericycle, Inc. (SRCL). Prior to joining Stericycle, he was senior vice president and chief financial officer with Telular Corp. Between 1991 and 1995, he was vice president and chief financial officer of Hexacomb Corp. Mr. ten Brink studied international business at the Netherlands School of Business and the University of Oregon, where he received a master of business administration degree in finance.

"We are privileged to have Frank join our board," commented John Patience, Accelerate Diagnostic's chairman. "In addition to his extensive background in finance and operations, his experience growing Stericycle from a $40 million early-stage company to the $1.9 billion leader it is today will be invaluable as we move forward."


Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections. We are focused on developing and commercializing innovative diagnostic systems for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company's revolutionary BACcel™ platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity.

In addition to the BACcel system development pipeline, Accelerate Diagnostics also owns and licenses its proprietary OptiChem® surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.


Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelerate Diagnostics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.

SOURCE Accelerate Diagnostics, Inc.